Nyxoah S.A.(NYXH)

Medical - Specialties · Mont-Saint-Guibert, WA

$1.42+0.01 (+0.71%)

Delayed quote: Oct 6, 2026, 3:36 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:42:43.429Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:42:43.429Z.

Quote observation: 2026-10-06T19:36:25.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 142,103,397
Total debt · period ending 2026-06-30: 60,042,118.24
Cash · period ending 2026-06-30: 73,230,870.7
TTM operating EBITDA · period ending 2026-06-30: -92,961,721.4042

FMP input reference: 88249fb6bbade3b4ad802b4bad00c79a42ee89cc3a650020707e3f27628c9d48

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NYXH EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

NYXH Competitors' EV/EBITDA Ratio

NYXH

Nyxoah S.A.

Current

Market Cap

$142.10M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FBIOP

Fortress Biotech, Inc.

vs NYXH

Market Cap

$144.06M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMRX

Immuneering Corporation

vs NYXH

Market Cap

$139.04M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STRO

Sutro Biopharma, Inc.

vs NYXH

Market Cap

$140.61M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TARA

Protara Therapeutics, Inc.

vs NYXH

Market Cap

$145.29M

EV/EBITDA Ratio

N/A

TTM Avg

44.23x

3Y Avg

44.23x

5Y Avg

44.23x

KRSA

Korsana Biosciences, Inc.

vs NYXH

Market Cap

$144.51M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NGEN

NervGen Pharma Corp. Common stock

vs NYXH

Market Cap

$145.70M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVXL

Anavex Life Sciences Corp.

vs NYXH

Market Cap

$145.96M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABOS

Acumen Pharmaceuticals, Inc.

vs NYXH

Market Cap

$146.26M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACOG

Alpha Cognition Inc

vs NYXH

Market Cap

$139.08M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Nyxoah S.A. (NYXH)	$142.10M	N/A	N/A	N/A	N/A
Fortress Biotech, Inc. (FBIOP)vs ›	$144.06M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$139.04M	N/A	N/A	N/A	N/A
Sutro Biopharma, Inc. (STRO)vs ›	$140.61M	N/A	N/A	N/A	N/A
Protara Therapeutics, Inc. (TARA)vs ›	$145.29M	N/A	44.23x	44.23x	44.23x
Korsana Biosciences, Inc. (KRSA)vs ›	$144.51M	N/A	N/A	N/A	N/A
NervGen Pharma Corp. Common stock (NGEN)vs ›	$145.70M	N/A	N/A	N/A	N/A
Anavex Life Sciences Corp. (AVXL)vs ›	$145.96M	N/A	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$146.26M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$139.08M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics